Korro Bio Doses First Patients in Phase 1/2 Trial for Rare Metabolic Drug
Korro Bio has dosed its first cohort in a Phase 1/2 trial of KRRO-121, targeting dangerous ammonia buildup in rare liver disorders.
Korro Bio, Inc. (Nasdaq: KRRO) announced Monday that the first group of participants has received doses in a Phase 1/2 clinical trial, known as ANCHOR, evaluating KRRO-121, an experimental RNA-editing therapy aimed at controlling toxic ammonia levels in patients with certain rare and serious liver-related conditions.
KRRO-121 is a GalNAc-conjugated RNA-editing oligonucleotide developed under Korro's proprietary OPERA platform, which stands for oligonucleotide promoted editing of RNA. The Cambridge, Massachusetts-based company is targeting two distinct patient populations: those with urea cycle disorders, a group of rare inherited diseases that impair the body's ability to remove ammonia, and those with hepatic encephalopathy, a serious complication of liver disease marked by ammonia-driven neurological decline.
Read more 101 Mobility Ranks No. 296 on Franchise Times Top 400 List →
The milestone marks a significant early-stage advancement for Korro's pipeline, as KRRO-121 represents one of a new class of genetic medicines seeking to correct disease at the RNA level rather than altering DNA directly. RNA-editing approaches have drawn growing interest from the biopharmaceutical sector as potentially safer and more reversible alternatives to traditional gene editing.
Korro Bio describes itself as a clinical-stage biopharmaceutical company focused on rare and highly prevalent diseases, positioning KRRO-121 as a potential treatment across both an ultra-rare inherited condition and a more broadly occurring complication of chronic liver disease. The breadth of the target indication could meaningfully expand the drug's commercial opportunity if clinical results prove favorable.
Continue reading at GlobeNewswire - Industry News on Financial Services.
